Using Your Own Bone Marrow Aspirate Concentrate to Treat Partial or Complete Anterior Cruciate Ligament Tears in Adults Aged 20 to 55

What this Trial Is About

This research aims to evaluate the use of autologous bone marrow aspirate concentrate BMAC to treat anterior cruciate ligament ACL tears, focusing on partial and complete tears without retraction. The ACL is essential for knee stability and is commonly injured in athletes. Traditional treatments vary from conservative care for partial tears to surgery for complete tears, but this study explores a regenerative medicine approach using BMAC to potentially promote healing and restore knee function. Participants receive a local injection of 4 cc of autologous bone marrow aspirate concentrate into the injured knee joint. The bone marrow is collected from the patient under local or general anesthesia by aspirating about 1-2 cckg of body weight, concentrated using centrifugation and a special disposable kit, then injected under ultrasound guidance in a sterile field. This is a single-arm study conducted at multiple centers. During the 6-month study, participants will undergo clinical assessments of ACL function and overall knee stability every 12 weeks. Magnetic resonance imaging MRI of the knee will be performed at 6 months to monitor structural changes. The study tracks functional recovery and joint stability to assess the potential benefits of BMAC treatment in ACL tears.

Bone Marrow Aspirate Concentrate for Anterior Cruciate Ligament Tear Treatment.